Novo Holdings, a leading international life science investor, on Thursday announced a £50m investment in Oxford Nanopore Technologies, the leading UK Listed company behind a new generation of molecular sensing technology based on nanopores. Oxford Nanopore is developing a transformational new generation of sensing technology that specialises in DNA/RNA sequencing. The £50m was invested by […]
Novo Holdings, a leading life science investor, on Tuesday announced that it has led a $105 million financing in Magenta Medical, developer of the Elevate™ System, the world’s smallest heart pump. The financing will be used to advance the company’s US clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first […]
On Tuesday, Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation a driver of neurodegenerative disease, announced it had secured a $100 million Series C Financing that was led by Novo Holdings. This financing will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment […]
Novo Holdings, a leading life science investor, on Monday announced that it has co-led a £90 million ($114 million) Series A financing for Myricx Bio, the largest European biotech Series A financing this year. Myricx Bio is a UK biotech company focusing on the discovery and development of a novel payload class for antibody-drug conjugates […]
Novo Holdings on Monday announced an initial investment in Danish food-tech start-up MATR Foods (‘MATR’) to support the scaling-up of its production of sustainable meat alternatives. Established in Copenhagen in 2021, MATR specialises in developing organic innovative plant-based meat alternatives using traditional fungal fermentation techniques. Locally sourced organic ingredients like oats, split peas, lupins, beetroots, […]
